Recursion licenses TxFM RNA foundation model to Tempus AI for oncology use in USD 12 million deal
Bitget2026/09/21 16:18- Recursion Pharmaceuticals expanded its data partnership with Tempus AI, extending the term to six years from the effective date.
- Revised annual license fees set at USD 14 million on each of the third, fourth, and fifth anniversaries, with at least USD 4 million paid in cash.
- Removed Recursion’s right to terminate for convenience; reduced the total unique de-identified records it can access over the term.
- Separate two-year oncology license grants Tempus use of Recursion’s TxFM RNA model; Tempus to pay USD 12 million in two installments.
- Tempus to provide access to de-identified pathology records with linked clinical data during the TxFM license term.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pi Network: Will mainnet KYC upgrades save PI crypto from drop to $0.076?
Why Is Tether Bringing USDT Back to Bitcoin Now? Morgan Stanley Offers a Clue
Swiss Franc: Dovish SNB keeps CHF under pressure against US Dollar – ING
Japan Central Bank inflation indicators accelerate, providing grounds for further interest rate hikes
An indicator used by the Bank of Japan to measure underlying inflation accelerated last month, significantly exceeding its target level, providing further justification for continuing to raise the benchmark interest rate.
Crypto prices
More
